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Abstract 
Haploidentical stem cell transplantation with T cell-replete grafts and post-transplant cyclophosphamide (PTCy) is 
increasingly used with encouraging outcome. Natural killer (NK) cell alloreactivity, predicted by missing killer cell 
immunoglobulin-like receptor (KIR) ligands in the recipient that are present in their donor improves outcome of T cell- 
depleted haploidentical transplants. We explored the role of KIR ligand mismatching in 444 acute leukemia patients after 
T cell-replete transplants with PTCy. Thirty-seven percent of all patients had KIR ligand mismatching. Patients were in first 
remission (CR1) (39%), second remission (CR2) (26%), or active disease (35%). Stem cell source was peripheral blood 
(PBSC, 46%) or bone marrow (54%). The 2-year relapse, non-relapse mortality (NRM), and survival rates were 36.0% 
(95% confidence interval (CI), 31.4–40.7), 23.9% (20.0–28.0), and 45.9% (40.8–51.0), respectively. Multivariate analysis 
identified acute myeloid leukemia compared with acute lymphoblastic leukemia (hazard ratio (HR) 0.55, P = 0.002), 
female gender (HR 0.72, P = 0.04), and good performance status (HR 0.71, P = 0.04) as factors associated with better 
survival, while advanced age (HR 1.13, P = 0.04), active disease (HR 3.38, P < 0.0001), and KIR ligand mismatching  
(HR 1.41, P = 0.03) as associated with worse survival. KIR ligand mismatching was associated with a trend for higher 
relapse but not with graft-versus-host disease or NRM. The KIR ligand-mismatching effect was more prominent in patients 
given PBSC. In conclusion, there is no evidence that KIR ligand mismatching results in better outcome in the PTCy setting. 
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Introduction 
 
Allogeneic hematopoietic stem cell transplant (SCT) is a 
potentially curative treatment for acute myeloid leukemia 
(AML) and acute lymphoblastic leukemia (ALL). Only 
about 1/3 of patients who require SCT have an available 
human leukocyte antigen (HLA)-matched sibling donor. A 
haploidentical-related donor can be identified in almost all 
patients. A haploidentical donor is most often readily 
available with no delays attributed to donor search, and can 
be easily approached for further stem cell or cellular 
therapies as needed. 
The initial results of haploidentical transplant using 
protocols that were similar to HLA-matched donor trans- 
plants were associated with a high risk for graft failure and 
severe graft-versus-host disease (GVHD) resulting in pro- 
hibitive non-relapse mortality (NRM) rate and dismal sur- 
vival [1, 2]. A regimen using extensive T cell depletion of 
donor graft, supplemented with the infusion of high stem 
cell dose and no post-transplant immune-suppressive ther- 
apy was able to overcome the HLA barrier of engraftment 
and GVHD, but was still associated with high NRM, due to 
slow immune reconstitution and infections [3]. Several 
post-transplant cellular therapies were explored trying to 
improve outcome; however, they require high level of 
expertise, are very costly, and cannot be applied in most 
transplant centers. 
Over the last decade, novel approaches using T cell- 
replete grafts were introduced. The most experience was 
gained by the use of post-transplant cyclophosphamide 
(PTCy) [4] and by the use of granulocyte-colony- 
stimulating factor (G-CSF)-primed marrow and peripheral 
blood stem cell (PBSC) harvesting and in vivo T cell 
depletion with anti-thymocyte globulin (ATG) and intensive 
post-transplant immune suppression (The Beijing 
Approach) [5]. These simple but effective methods have 
allowed a marked increase in the use of haploidentical 
donors in recent years [6]. Several retrospective compara- 
tive studies have shown that these T cell-replete haploi- 
dentical transplant are associated with comparable 
outcomes with HLA-matched sibling and unrelated donor 
transplants (reviewed in [7, 8]). 
Most patients will have more than one available hap- 
loidentical donors and several algorithms have been 
developed to select the best donor [7, 9–12]. These algo- 
rithms considered donor age, gender, and family relations, 
as well as HLA and blood group compatibility, CMV status, 
and the finding of host donor-specific antibodies as 
important factors. Natural killer (NK) cell alloreactivity has 
a documented role in haploidentical T cell-depleted SCT 
[13, 14]. NK cells are an essential part of the innate immune 
system directed against malignancy and infections [15, 16]. 
NK cell function is regulated by a complex of inhibitory and 
 
activating receptors as well as co-modulating receptors. The 
main receptors belong to the killer cell immunoglobulin-like 
receptor (KIR) family. The major ligands for inhibitory 
KIRs belong to HLA C and are grouped as C group 1 and C 
group 2, based on polymorphism at residue 80 in the HLA 
C molecule or to Bw4 epitopes. When an inhibitory KIR 
engages its ligand, the NK cell becomes inhibited. Leuke- 
mia cells and infected cells often down-regulate HLA and 
thus become susceptible to killing by NK cells. Donor NK 
cells may become activated against host cells when the host 
lacks a ligand that is present in the donor (missing self 
model). KIR ligand mismatching in the graft-versus-host 
direction was associated with lower relapse rates as well as 
better engraftment and lower rates of GVHD in T cell- 
depleted haploidentical transplants [13, 14]. However, there 
is limited data on the role of NK alloreactivity in T cell- 
replete haploidentical transplants [17–21]. 
In this study, we show in a relative large registry study of 
haploidentical transplants with PTCy that KIR ligand mis- 
matching may be associated with a worse outcome, espe- 
cially in patients having PBSC transplants, and 
haploidentical donors with KIR ligand mismatching should 
not be preferred. 
 
 
Patients and methods 
Study design and data collection 
 
This is a retrospective multicenter analysis. Data were 
provided and approved for this study by the Acute Leuke- 
mia Working Party of the European Society for Blood and 
Marrow Transplantation (EBMT). The latter is a voluntary 
working group of more than 500 transplant centers that are 
required to report all consecutive SCTs and follow-ups once 
a year. Audits are routinely performed to determine the 
accuracy of the data. The study protocol was approved by 
the institutional review board at each site and complied with 
country-specific regulatory requirements. The study was 
conducted in accordance with the Declaration of Helsinki 
and Good Clinical Practice guidelines. All patients provided 
written informed consent authorizing the use of their per- 
sonal information for research purposes. Eligibility criteria 
included patients with de novo AML or ALL in any disease 
status at SCT, following transplants from haploidentical 
relative (with at least two HLA mismatches) between the 
years 2009 and 2015. GVHD prophylaxis included post- 
transplant high-dose cyclophosphamide in all patients. 
Grafts were from the bone marrow (BM) or PBSC and were 
all T cell replete. Ex-vivo T cell depletion was not allowed. 
HLA typing was based on high-resolution typing of class I 
and class II HLA antigens. Patient KIR ligand typing was 
defined according to HLA typing. Patients were divided 
  
 
into a group with and a group with no KIR ligand mis- 
matching in the graft-versus-host direction as previously 
described. Patient and donor KIR genotyping was not 
available. Variables collected included recipient and donor 
characteristics, disease features, transplant-related factors 
including drugs and total doses used in the conditioning 
regimen, and outcome variables. 
 
Conditioning regimens 
 
The conditioning regimen was selected according to the 
participating center discretion. Dose intensity was defined 
according to standard criteria based on the reversibility and 
expected duration of cytopenia after SCT [22]. GVHD 
prophylaxis was selected according to the participating 
center policy and consisted of a calcineurin inhibitor 
(cyclosporine A or tacrolimus) and mycophenolate mofetil 
in addition to PTCy in most patients. ATG was allowed 
according to the participating center policy. 
 
Evaluation of outcomes 
 
Disease relapse was defined according to standard hema- 
tological criteria. NRM was defined as death of any cause in 
the absence of prior disease recurrence. Leukemia-free 
Survival (LFS) was defined as survival without relapse. 
Overall survival (OS) was calculated from the day of SCT 
until death of any cause or last follow-up. Patients with no 
event were censored at last contact. The cause of death was 
categorized according to standard criteria. The cause of 
death of patients who experienced relapsed disease at any 
time prior to death was considered relapse related. Acute 
and chronic GVHD were graded according to standard 
criteria. 
 
Statistical analysis 
 
The primary end point of the study was OS. Secondary 
endpoints included acute and chronic GVHD, NRM, relapse 
incidence, and LFS. All outcomes were measured from the 
time of stem cell infusion. The two patient KIR ligand 
groups were compared by the χ2 method for qualitative 
variables, and Mann–Whitney test for continuous para- 
meters. LFS and OS were estimated using the Kaplan–
Meier method [23], while NRM, relapse, and GVHD were 
estimated using cumulative incidence analysis considering 
competing risks [24]. Univariate comparisons were done 
using the log-rank test for LFS and OS, and Gray’s test for 
GVHD, relapse incidence (RI), and NRM. For all 
univariate analyses, continuous variables were categorized 
and the median was used as a cut-off point. Multivariate 
analyses were performed using Cox propor- tional hazards. 
Variables were included in the multivariate 
 
Table 1 Patient characteristics 
 
 KIR mismatched KIR matched P value 
(n = 165) (n = 279)  
Age (median, 
range), years 
47 (19–78) 46 (18–75) 0.48 
Gender (male) 59% 60% 0.91 
Diagnosis    
AML 73% 74% 0.74 
ALL 27% 26%  
Disease status    
CR1 36% 41% 0.36 
CR2 25% 26%  
Active disease 39% 33%  
CMV status    
D−/R− 11% 10% 0.16 
D+/R+ 9% 8%  
D−/R+ 13% 21%  
D+/R+ 67% 61%  
Performance status 
(KS ≥ 90) 
68% 63% 0.35 
Donor age (median, 
range), years 
40 (13–74) 37 (13–72) 0.15 
Donor gender 
(male) 
55% 57% 0.65 
Stem cell source    
BM 54% 53% 0.91 
PBSC 46% 47%  
Conditioning regimen    
MAC 58% 51% 0.17 
RIC 42% 49%  
GVHD prophylaxis    
CSA + MMF 45% 48% 0.15 
MMF + Siro 10% 6%  
MMF + Tacro 40% 37%  
Other 5% 9%  
Time from 
diagnosis (median, 
range) 
8 (2–146) 8 (2–119) 0.9 
Year of SCT 
(median, range) 
2013 
(2009–2015) 
2013 
(2009–2015) 
0.58 
KIR killer immunoglobulin-like receptor, AML acute myeloid 
leukemia, ALL acute lymphoblastic leukemia, D donor, R recipient, 
KS Karnofsky performance score, GVHD graft-versus-host disease, 
BM bone marrow, PBSC peripheral blood stem cells, MAC 
myeloablative conditioning, RIC reduced-intensity conditioning, CSA 
cyclosporine A, MMF mycophenolate mofetil, Siro sirolimus, Tacro 
tacrolimus, SCT stem cell transplantation 
 
 
model if they were conceptually important or if they differ 
in terms of distribution between the two groups. Results are 
expressed as hazard ratio (HR) with 95% confidence 
interval (CI). Analyses were also stratified by disease (AML 
or ALL) and source of stem cells. To test for a center effect, 
  
 
we introduced a random effect or frailty for each center into 
the model. All p values were two-sided and values <0.05 
were considered statistically significant. Statistical analyses 
were performed with SPSS 22.0 (IBM Corp., Armonk, NY, 
USA) and R3.2.3 software packages (R Development Core 
Team, Vienna, Austria). 
 
 
Results 
Patient characteristics 
 
The study included 444 patients with AML (n = 327) or 
ALL (n = 117) given haploidentical transplant with PTCy 
during the years 2009–2015. Patient characteristics are 
outlined in Table 1. The median age was 46 years (range, 
18–78 years). The median donor age was 39 years (range, 
13–74 years) and 24% of transplants were from a female 
donor to a male recipient. The median time from diagnosis 
to transplantation was 8 months (range, 2–146 months). 
Patients were in first remission (CR1) (39%), second 
remission (CR2) (26%), or active disease (35%) at the time 
of transplantation. Stem cell source was PBSC (46%) or 
BM (54%). The conditioning regimen was myeloablative 
conditioning (MAC, 54%) or reduced-intensity condition- 
ing (RIC, 46%). The GVHD prevention regimen included 
cyclosporine or tacrolimus with mycophenolate, in addition 
to PTCy in 85% of patients. 
HLA typing of recipients and donors showed that 105 
patients (25%) lacked an HLA C group 1 or 2 antigen that 
was present in the donor. Seventy-nine patients (15%) 
lacked a Bw4 antigen that was present in their donor. In all, 
165 patients (37%) had KIR ligand mismatching in the 
graft-versus-host direction according to the missing self 
model. There was no difference in patient characteristics 
between patients with or without KIR ligand mismatching 
(Table 1). We have also analyzed KIR ligand mismatching 
according to the missing ligand model, which considered 
only host missing ligands, irrespective of their expression in 
the donor. In all, 331 patients (69%) missed at least one C 
group 1, C group 2, or Bw4 ligand. The missing ligand 
theory did not explain any of the transplantation outcomes 
and will not be further discussed. 
 
Engraftment and GVHD 
 
Patients (92.3%) had neutrophil engraftment with a median 
time to engraftment of 18 days (range, 8–47 days). The rate 
of engraftment was 93.2% in KIR ligand-matched and 
89.9% in KIR ligand-mismatched recipients (P = 0.44). The 
median  time  to  engraftment  was  18  days  (range,  11–
47 days) and 18 days (range, 8–34 days), respectively (P = 
0.87). 
The cumulative incidence of acute GVHD grade II–IV 
was 28.3% (95% CI, 24.5–32.3). Multivariate analysis 
identified PBSC transplantation compared to BM (HR 2.10, 
P = 0.0004) and transplantation from a female donor (HR 
1.42, P = 0.07) as factors predicting for increased rates of 
acute GVHD (Table 2). Acute GVHD was less common in 
patients with AML compared to ALL (HR 0.63, P = 0.03). 
The rate of acute GVHD grade II–IV was 24.1% (95% CI, 
17.6–31.1) and 32.2% (95% CI, 26.7–37.9) in patients with 
and without KIR ligand mismatching, respectively (P = 
0.08). However, KIR ligand mismatching was not an 
 
Table 2 Multivariate analysis of pre-transplant factors predicting for acute and chronic GVHD 
 
Factor Acute GVHD grade II–IV   Chronic GVHD  
 HR (95% CI) P value HR (95% CI) P value 
Age (per 10 years) 0.98 (0.86–1.11) 0.72  0.91 (0.76–1.08) 0.27 
Gender (female Vs male) 1.27 (0.88-1.85) 0.21  0.72 (0.48-1.19) 0.23 
Diagnosis (AML vs ALL) 0.63 (0.41-0.96) 0.03 1.19 (0.95-1.49) 0.13 
CR2 vs. CR1 1.27 (0.79-2.03) 0.32 0.84 (0.50-1.42) 0.52 
Advanced vs. CR1 1.37 (0.86-2.18) 0.19 1.17 (0.64-2.14) 0.61 
KPS ≥ 90 1.10 (0.73-1.65) 0.66 0.74 (0.45-1.21) 0.23 
Donor gender (Female vs. male) 1.42 (0.97-2.06) 0.07 0.92 (0.58-1.47) 0.72 
KIR mismatching (mismatched vs. matched) 0.73 (0.48-1.09) 0.12 0.87 (0.53-1.44) 0.59 
Stem cell source (PBSC vs BM) 2.10 (1.40-3.16) 0.0004 1.04 (0.53-2.01)(4 0.92 
Conditioning regimen (RIC vs MAC) 0.76 (0.51-1.16) 0.20 0.81 (0.46-1.43) 0.47 
GVHD prophylaxis 
Tacro + MMF (vs CSA+MMF) 
 
0.88 
 
(0.57-1.36) 
 
0.56 
 
1.87 (0.79-4.40) 
 
0.15 
Other 0.96 (0.56-1.64) 0.88 2.07 (0.91-4.73) 0.08 
Center (frailty variable)   0.92  0.007 
AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, GVHD graft-versus-host disease, CR1 first remission, CR2 second remission, 
KPS Karnofsky performance score, BM bone marrow, PBSC peripheral blood stem cells, KIR killer immunoglobulin-like receptor, MAC 
myeloablative conditioning, RIC reduced-intensity conditioning, CSA cyclosporine A, MMF mycophenolate mofetil, Tacro tacrolimus, HR hazard 
ratio, CI confidence interval 
  
 
 
 
Fig. 1 Transplantation outcomes after T cell-replete haploidentical 
transplant in the entire patient group (n = 444). Cumulative incidence 
curves of relapse incidence (RI) and non-relapse mortality (NRM) and 
Kaplan–Meier curves of overall survival (OS) and leukemia-free 
survival (LFS) are compared between patients with KIR ligand- 
matched donors (solid line) and patients with KIR ligand-mismatched 
donors in the GVHD direction (dashed line) 
 
independent factor in the multivariate analysis (HR 0.73, P 
= 0.12). 
The cumulative incidence of chronic GVHD was 33.3% 
(95% CI, 28.6–38). The multivariate analysis could not 
identify any significant predicting factor for chronic GVHD 
(Table 2). In particular, KIR ligand mismatching was not 
associated with chronic GVHD (HR 0.87, P = 0.59). 
 
Relapse and non-relapse mortality 
 
The 2-year relapse and NRM rates in the entire group were 
36.0% (95% CI, 31.4–40.7) and 23.9% (95% CI, 20.0–8.0), 
respectively (Fig. 1). Multivariate analysis identified disease 
status at transplantation as the most significant factor pre- 
dicting relapse (HR 5.17, P < 0.0001 and HR 1.65, P = 0.06 
for active disease and CR2, respectively, compared with 
CR1 at transplantation). RIC was associated with higher 
incidence than MAC (HR 1.57, P = 0.03). There was a 
trend for higher relapse rates in patients with KIR ligand 
mismatching (HR 1.36, P = 0.09). This trend was seen in 
patients with AML (HR 1.48, P = 0.07) but not when the 
analysis was limited to patients with ALL (HR 0.95, P = 
0.88).  Relapse  was  less  common in AML compared with 
ALL (HR 0.64, P = 0.05). RI was also lower in female 
patients and after transplantation from female donors 
(Table 3). 
The predicting factors for NRM were active disease at 
transplantation (HR 1.73, P = 0.05) and advanced age (P = 
1.38, P = 0.0004). AML (HR 0.59, P = 0.05), good per- 
formance status (HR 0.74, P = 0.07) and PBSC (HR 0.56, 
P = 0.07) were associated with a lower incidence of NRM 
(Table 3). A strong center effect was also detected in the 
incidence of NRM (P = 0.001). KIR ligand mismatching 
was not a significant factor for NRM (HR  1.29, P = 0.28). 
 
Leukemia-free survival and overall survival 
 
With  a  median  follow-up  of   14   months   (range,   1–
70 months), 236 patients are alive and 208 have died. The 
LFS and OS rates were 39.2% (95% CI, 34.3–44.1) and 
45.9% (95% CI, 40.8–51.0), respectively. The major causes 
of death were disease recurrence (n = 82), GVHD (n = 28), 
infection (n = 68), and others (n = 30). The status of disease 
at transplantation was the most important factor predicting 
OS. The 2-year OS was 66.8% (95% CI, 59.4–74.3), 56.6% 
(95% CI, 47.4–65.9), and 28.8% (95% CI, 21.0–36.5) in 
  
 
Table 3 Multivariate analysis of pre-transplant factors predicting for relapse and non-relapse mortality 
 
Factor Relapse   Non-relapse mortality  
 HR (95% CI) P value  HR (95% CI) P value 
Age (per 10 years) 0.83 (0.72–0.95) 0.006  1.38 (1.16–1.65) 0.0004 
Gender (Female vs. male) 0.61 (0.41–0.90) 0.01  1.08 (0.69–1.68) 0.74 
Diagnosis (AML vs. ALL) 0.64 (0.40–1.00) 0.05  0.59 (0.35–1.00) 0.05 
CR2 vs. CR1 1.65 (0.98–2.76) 0.06  0.95 (0.53–1.69) 0.86 
Advanced vs. CR1 5.17 (3.23–8.29) <0.0001  1.73 (1.00 2.99) 0.05 
KPS ≥ 90 0.79 (0.54–1.16) 0.22  0.74 (0.45–1.04) 0.07 
Donor gender (Female vs. male) 0.65 (0.45–0.94) 0.02  0.89 (0.57–1.40) 0.82 
KIR mismatching (Mismatched vs. matched) 1.36 (0.94–1.95) 0.09  1.29 (0.81–2.04) 0.28 
Stem cell source (PBSC vs. BM) 1.21 (0.83–1.77) 0.32  0.56 (0.30–1.06) 0.07 
Conditioning regimen (RIC vs. MAC) 1.57 (1.04–2.36) 0.03  1.01 (0.61–1.66) 0.98 
GVHD prophylaxis 
Tacro + MMF (vs. CSA + MMF) 
 
0.63 (0.40–0.97) 
 
0.04 
  
1.61 (0.82–3.18) 
 
0.17 
Other 1.02 (0.59–1.74) 0.95  3.89 (1.87–8.11) 0.0003 
Center (frailty variable)  0.92   0.001 
AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, GVHD graft-versus-host disease, CR1 first remission, CR2 second remission, 
KPS Karnofsky performance score, BM bone marrow, PBSC peripheral blood stem cells, KIR killer immunoglobulin-like receptor, MAC 
myeloablative conditioning, RIC reduced-intensity conditioning, CSA cyclosporine A, MMF mycophenolate mofetil, Tacro tacrolimus, HR hazard 
ratio, CI confidence interval 
 
Table 4 Multivariate analysis of pre-transplant factors predicting for leukemia-free survival and overall survival 
 
Factor LFS   OS  
 HR (95% CI) P value  HR (95% CI) P value 
Age (per 10 years) 1.01 (0.91–1.13) 0.80  1.13 (1.01–1.27) 0.04 
Gender (Female vs. male) 0.74 (0.55–0.99) 0.04  0.72 (0.53–0.99) 0.04 
Diagnosis (AML vs. ALL) 0.59 (0.42–0.83) 0.002  0.55 (0.38–0.80) 0.002 
CR2 vs. CR1 
Advanced vs. CR1 
1.25 (0.86–1.83) 
3.13 (2.20–4.46) 
0.25 
<0.0001 
 1.44 (0.96–2.16) 
3.38 (2.26–5.04 
0.08 
<0.0001 
KPS ≥ 90 0.74 (0.55–1.00) 0.05  0.71 (0.51–0.98) 0.04 
Donor gender (Female vs. male) 0.82 (0.62–1.09) 0.17  0.81 (0.59–1.10) 0.18 
KIR mismatching (Mismatched vs. matched) 1.29 (0.97–1.73) 0.08  1.41 (1.03–1.93) 0.03 
Stem cell source (PBSC vs. BM) 0.89 (0.64–1.25) 0.51  0.83 (0.55–1.23) 0.55 
Conditioning regimen (RIC vs. MAC) 1.28 (0.93–1.77) 0.13  1.24 (0.88–1.76) 0.22 
GVHD prophylaxis 
Tacro + MMF (vs. CSA + MMF) 
 
0.95 (0.63–1.43) 
 
0.81 
  
1.27 (0.79–2.04) 
 
0.32 
Other 1.62 (1.03–2.54) 0.04  1.95 (1.14–3.31) 0.01 
Center (frailty variable)  0.05   0.005 
AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, GVHD graft-versus-host disease, CR1 first remission, CR2 second remission, 
KPS Karnofsky performance score, BM bone marrow, PBSC peripheral blood stem cells, KIR killer immunoglobulin-like receptor, MAC 
myeloablative conditioning, RIC reduced-intensity conditioning, CSA cyclosporine A, MMF mycophenolate mofetil, Tacro tacrolimus, HR hazard 
ratio, CI confidence interval, LFS leukemia-free survival, OS overall survival 
 
 
CR1, CR2, and active disease, respectively (P < 0.0001). 
The 2-year OS was 46.8% (95% CI, 38.2–55.3) in patients 
with KIR ligand mismatching and 53.1% (95% CI, 46.4–
59.7) in patients with no KIR ligand mismatching   (P = 
0.11, Fig. 1). Multivariate analysis identified AML 
(compared to ALL) (HR 0.55, P = 0.002), female gender 
(HR 0.72, P = 0.04), and good performance status (HR 
0.71, P = 0.04) as factors associated with better survival, 
while advanced age (HR 1.13, P = 0.04), active disease 
(HR 3.38, P < 0.0001), and KIR ligand mismatching (HR 
1.41, P = 0.03) were factors associated with worse survival 
(Table 4). A center effect was also evident in predicting OS 
(P = 0.005). The role of KIR ligand mismatching was more 
evident in AML. The HRs in multivariate analysis for OS 
were HR 1.42 (P = 0.07) in AML and HR 1.63 (P = 0.15) 
in ALL. 
The negative effect of KIR ligand mismatching was more 
prominent in patients given PBSC compared with BM. 
Among PBSC recipients OS was 51.0% (95% CI, 41.8–60.3) 
and 34.5% (95% CI, 21.8–47.2) after KIR ligand-matched 
and KIR ligand-mismatched transplants (Fig. 2, P = 0.02). 
This was mostly related to higher relapse rates in the KIR 
ligand-mismatched group, 46.7% (34.4–58.2) and 32.2% 
(24.1–40.6), respectively (P = 0.05). Multivariate analysis 
  
 
 
Fig. 2 Transplantation outcomes after T cell-replete haploidentical transplant among patients given peripheral blood stem cell grafts (n = 238). 
Similar curves to Fig. 1 
 
limited to PBSC recipients showed that the HRs of KIR 
ligand mismatching for relapse, NRM, LFS, and OS were 
1.97 (P = 0.005), 1.30 (P = 0.41), 1.60 (P = 0.02), and 1.60 
(P = 0.03), respectively. No similar significant difference 
was identified in BM recipients, with a 2-year OS of 44.7% 
(34.6–54.8) and 45.1% (32.4–57.9) after KIR ligand-matched 
and KIR ligand-mismatched transplants, respectively (P = 
0.93). There was no significant difference in the KIR ligand- 
mismatching effect in the subgroup analysis according to 
conditioning intensity or disease status at SCT (data not 
shown). 
 
 
Discussion 
 
Haploidentical transplant with PTCy is increasingly used as 
a valid transplantation approach in acute leuekmia [6]. The 
current study confirms in a relatively large multicenter 
registry study of 444 patients with acute leukemia, the 
feasibility and relatively favorable outcome of this 
approach. The 2-year survival rates of 67%, 57%, and 29% 
in patients in CR1, CR2, and active disease, respectively, 
compared with the survival rates expected after matched 
donor transplants. Similarly, a CIBMTR study of 192 
patients with AML following haploidentical transplant 
with PTCy showed a 3-year OS of 45% that was not 
different from a comparative group of unrelated donor 
transplants [25]. Other, smaller studies suggested similar 
trends [26–28]. Several donor, conditioning regimen, and 
stem cell source factors can be manipulated attempting in 
improving outcome. The degree of HLA matching and the 
specific HLA disparities are not associated with transplan- 
tation outcomes [29, 30]. However, the current study shows 
that KIR ligand mismatching in the graft-versus-host 
direction, as predicted by missing recipient HLA KIR 
ligands that are present in the donor (missing self model) is 
associated with increased relapse rate and worse survival 
after transplantation, especially when PBSCs are used as 
stem cell source. 
The Perugia group has clearly shown that in the context 
of extensive T cell depletion, high stem cell dose, and no 
post-transplant immune suppression, NK alloreactivity as 
predicted by the missing self model reduces the risk of 
relapse and markedly improve survival for patients with 
AML but not ALL [13, 14]. NK alloreactivity also reduced 
the rate of GVHD by eliminating host antigen-presenting 
cells. Alloreactive T cells persisted for up to 12 months 
before becoming tolerized to the recipient. Activating KIR 
further enhanced the benefit of KIR ligand mismatching, 
mostly by reducing NRM [31]. 
  
 
Contradictory results were reported in haploidentical 
transplants using less vigorous T cell depletion. Bishara    
et al. [32] reported that following a regimen allowing a 
somewhat larger T cell content, NK alloreactivity was 
associated with increased rates of acute GVHD and NRM, 
and poorer OS, although with similar engraftment and 
relapse rates. Activating KIRs also increased the risk of 
GVHD. These authors suggested that the benefit of NK 
alloreactivity may be less clear in the presence of GVHD 
caused by residual donor T cells. Cooley et al. [33] have 
shown in the context of unrelated donor transplants that  
KIR reconstitution and NK cell function are adversely 
affected by T cells in the graft. 
There is only limited and emerging data on the role of 
NK alloreactivity in non-T cell-depleted haploidentical 
transplants. Russo et al. [17] explored the dynamics of NK 
cell reconstitution in a group of 17 recipients of haploi- 
dentical SCT with PTCy. They showed robust proliferation 
of donor-derived NK cells, with a mature phenotype, 
immediately after transplant. However, within days after the 
infusion of PTCy there was a marked reduction of pro- 
liferating NK cells including single KIR positive that 
include alloreactive NK cells. A second wave of recon- 
stituting NK cells started appearing about 2 weeks after 
SCT. These cells were predominantly with an immature 
phenotype and with an impaired antileukemic effect com- 
pared with their mature donor counterparts. The phenotypic 
recovery of mature NK cells stemming from engrafting 
donor stem cells took several months to 1 year after trans- 
plant. As a consequence, in an extended series of 99 hap- 
loidentical transplants with PTCy, no significant survival 
difference was found between patients with or without 
predicted NK alloreactivity. Interestingly, patients with 
rapid reconstitution of mature phenotype, including 
expression of KIR, had a better outcome. 
The Chinese group, using ATG-based intensive immune 
suppression with G-CSF mobilized BM and PBSC, have 
shown that KIR ligand mismatching as predicted by the 
missing self model was associated with higher relapse rates 
and worst survival [18]. KIR ligand mismatching was 
associated with higher rates of acute GVHD, especially in 
the group given a higher T cell content within the graft, but 
in all NRM was similar. These data suggest that the bene- 
ficial NK alloreactivity may be inhibited by the large dose 
of T cells given in this protocol. The Chinese group further 
showed that patients presenting HLA class I ligands for 
donor inhibitory KIRs had more functional NK effector 
cells when tested against K562 cell lines and primary leu- 
kemia cells [19]. During maturation, NK cell require 
recognition of their self KIR ligand to acquire full func- 
tionality in a process called licensing [15, 16]. While most 
studies have shown that NK cell licensing after SCT is 
determined by donor cells [34], the Chinese group data 
suggest that in their transplant setting host cells are pro- 
moting NK cell licensing and thus KIR ligand matching 
rather than mismatching protects from relapse. The con- 
tradictory results with the Perugia group may be explained 
by the assumption that a high stem cell dose may favor an 
environment where NK cells are licensed by donor cells 
[20]. Thus, the Russo study showed that PTCy eliminated 
the majority of mature alloreactive NK cells transferred 
within the graft, thus blunting the favorable impact of KIR 
ligand mismatching. The Chinese data further support a 
negative effect of KIR ligand mismatching by impairing NK 
licensing and rapid NK cell reconstitution after transplant. 
Symons et al. [21] reported the NK effect in a group of 
86 patients with various hematological malignancies, given 
nonmyeloablative haploidentical BM transplants with 
PTCy, in the Johns Hopkins University. In this group, KIR 
ligand mismatching was associated with improved relapse 
rate, similar NRM, and better survival rates. Patients with 
homozygous A haplotypes had a better outcome if the 
donor had at least one B haplotype. NK mismatching was 
defined as any mismatch in KIR genes, but the more 
common missing self or missing ligand models were not 
associated with outcome. 
Our results are more similar to the Chinese data using 
ATG-based conditioning than to the Johns Hopkins data 
using PTCy. Differences in patient characteristics, con- 
ditioning regimens, graft content, and post-transplant 
immune-suppressive therapy may explain these differ- 
ences. In particular, our study used PBSC in 46% of 
patients, a subset where the adverse effect of KIR ligand 
mismatching was more evident. The Chinese group used 
PBSC with G-CSF mobilized BM in all patients, and the 
Johns Hopkins group used BM exclusively. T cell content 
of the graft may have a major contribution to these different 
observations. PTCy depletes alloreactive T cells and NK 
cells that become activated against host antigens in the early 
days after transplantation. As discussed activated T cells 
may interfere with NK activity in T cell-replete transplant, 
especially when administered in a larger T cell dose. Donor 
regulatory T cells (T-regs) are resistant to PTCy, owing to 
increased expression of aldehyde dehydrogenase, the 
enzyme primarily responsible for detoxification of cyclo- 
phosphamide [35]. T-reg expansion or predominance is 
essential for the PTCy effect [8]. However, pre-clinical 
studies suggest active cross-talk between NK cells and T- 
regs. T-regs can prevent NK cytotoxicity and cytokine 
production [36]. This complex interplay may have an effect 
on the relative role of NK cells in the different transplan- 
tation settings. Similar to the experience in T cell-depleted 
transplant, the NK effect was less evident in ALL than in 
AML. Overall outcome was also less favorable in ALL;  
however, haploidentical transplant is a valid treatment 
option in ALL [37]. 
  
 
In conclusion, T cell-replete haploidentical transplanta- 
tion with PTCy is a feasible and effective approach in 
patients with acute leukemia with expected outcomes that 
are similar to HLA-matched donors. Unlike haploidentical 
transplants with T cell depletion, there is no evidence that 
selecting NK alloreactive donors provide better outcome in 
the T cell-replete transplant with PTCy setting. KIR ligand 
mismatching may even need to be avoided when PBSCs are 
selected as the stem cell source. 
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